Howard Kaufman, MD

Howard Kaufman, MD

Episodes

Specialty:

All

Year:

All

EP. 1: The Evolution of Immunotherapy in Cancer

June 20th 2016

EP. 2: Patient Selection for Checkpoint Inhibitor Therapy and Assessing Response

June 20th 2016

EP. 3: Emerging Checkpoint Inhibitors and Therapeutic Oncolytic Viruses

June 20th 2016

EP. 4: Adoptive T-Cell Approaches and Tumor Vaccine Strategies

June 20th 2016

EP. 5: The Future and the Era of Precision Immunology

June 20th 2016

EP. 6: Managing Avelumab Side Effects in Patients With Merkel Cell Carcinoma

June 20th 2016

EP. 7: Emerging Agents in the Pipeline for Merkel Cell Carcinoma

June 20th 2016

EP. 8: Role of Immunotherapy in Merkel Cell Carcinoma

June 20th 2016

Trending on OncLive

Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma

ESMO Guidelines Express Update Recommends Daraxonrasib for RAS G12–Mutated Metastatic PDAC

Mo-Rez Advances Into Combination Studies Following Robust Responses in Gynecologic Cancers

mRNA Vaccines May Help Increase Long-Term Disease Control in PDAC

FDA Grants Fast Track Designation to PLN-101095 Plus Pembrolizumab in Solid Tumors